Clinical

Cardiology: NICE recommends new treatment for people with common heart condition

In final draft guidance, NICE has recommended Apixaban (Eliquis, Bristol-Myers Squibb and Pfizer), in accordance with its licensed indications, for the prevention of stroke and systemic embolism in some people with non-valvular atrial fibrillation.

The draft guidance also recommends that the decision about whether to start treatment with apixiban should be made after an informed discussion about the risks and benefits of apixaban compared with warfarin, dabigatran etexilate and rivaroxaban, and in light of a person’s current level of international normalised ratioi (INR) control if they are already taking warfarin.

Read more.

Bookmark and Share

Post a Comment

Enter this security code

Submit Comment for Moderation